Research and development

Just twenty years ago, the medical use of the cannabis plant was still in its infancy. The companies THC Pharm and Bionorica ethics were the first in Germany to recognize the far-reaching potential of this plant for treatment in many indication areas. Since then, continuous investment in research and development has made it possible to steadily gain new insights into both the active ingredients as well as their pharmacological and medical potential. Through the merger of THC Pharm and Bionorica ethics under the umbrella of C³-Holding GmbH, the synergy potential of the two manufacturers could be exploited for the purpose of a focused research strategy.

Bionorica ethics in Neumarkt/Upper Palatinate isolates dronabinol in pharmaceutical quality and cannabidiol in food quality from medical cannabis flowers. THC Pharm, based in Frankfurt am Main, synthesizes dronabinol and cannabidiol in GMP-compliant pharmaceutical quality in high-tech chemical processes. In addition to synthesizing THC and CBD for therapeutic purposes, THC Pharm is the market leader in the production of high-purity cannabinoid reference substances for analytical and other laboratory applications. Two completely different manufacturing processes and two different production sites for cannabinoids were thus united under the umbrella of C³.

Ill. Manufacturing processes

GMP-compliant manufacturing processes

Ill. Cannabinoid reference substances

Production of high-purity cannabinoid reference substances for analytical applications

Ill. Research and development

20 Years experience in research and development

Ill. Structure

Areas of Interest

C3 is marketing a magistral formulation of dronabinol (THC) which is the purified main psychoactive cannabinoid of the cannabis plant. In some countries it can be used for various indications/ conditions upon prescription of the treating physician. Although the cannabis plant is used for thousands of years for medical purposes, there is still a lack of systematic evaluation of its benefits.

In addition we are constantly looking to expand our research by external research collaborations. If you are a principal investigator or a researcher interested in submitting a proposal for an investigator initiated study (IIS), either non-clinical or clinical, please contact us (info@c3-company.de).

Areas of interest for IIS proposals with dronabinol are therefore for example
(but explicitly not limited to):

  • Chronic pain (e.g. central neuropathic pain, peripheral neuropathic pain, postherpetic neuralgia, trigeminus neuralgia)
  • Oncology (e.g. anti-cancer, chemotherapy-induced peripheral neuropathy, quality of life)
  • Psychiatric disorders (e.g. PTSD)
  • Neurological disorders (e.g. spasticity, agitation due to Alzheimer’s disease, Tourette syndrome, tremor in Parkinson's disease)
  • Gastrointestinal disorders (e.g. functional disorders due to inflammatory bowel diseases; irritable bowel syndrome)
  • Disease-related symptoms (e.g. cachexia, anorexia, sleep quality, quality of life)
  • Health-economical investigations (e.g. alternative therapy regimen, reduction of comedication/analgetics)
  • Special patient populations (e.g. certain concomitant diseases / multimorbidity / palliative)
  • Pharmacodynamic studies

If you are interested in submitting a proposal for an investigator initiated study (IIS), either non-clinical or clinical, please contact us for further information (info@c3-company.de).

Ill. Structure
Ill. Structure
Ill. Structure